Table SI. Clinicopathological characteristics of the patients.

Case	Age, years	Sex	Stage	Grade	LVI	Adjuvant 5-FU	Initial relapse site
1	80	М	T1NxM0	1	_	-	_
2	69	М	T1NxM0	1	-	-	-
3	74	М	T1NxM0	2	-	-	-
4	59	М	T3N0M0	3	+	-	RPLN
5	71	F	T3N0M0	3	+	-	RPLN
6	76	F	T4N0M0	3	+	-	Lumbar bone
7	51	M	T4N0M0	3	+	_	RPLN
8	74	F	T4N1M0	3	+	_	Local recurrence
9	69	M	T3N0M0	2	+		
10	64	F	T4N0M0	3	+		RPLN
10	73	F	T1NxM0	2	т	-	Ureter
11	73 79	M	T3N0M0	3	-	-	
12	79 74	F			+	-	Lung
			T1NxM0	2	-	-	-
14	65 75	М	T3N0M0	2	+	+	-
15	75	F	T3NxM0	3	-	-	RPLN
16	71	М	T3N1M0	3	+	-	RPLN
17	64	Μ	T2NxM0	3	-	-	Urinary bladder
18	68	М	T1NxM0	2	+	+	Urinary bladder
19	73	F	T2NxM0	2	+	+	-
20	66	Μ	T3N0M0	2	+	+	-
21	76	F	T4N1M0	3	+	-	Liver
22	72	Μ	T3N1M0	3	+	-	Lung
23	54	Μ	T2NxM0	3	-	-	RPLN
24	68	М	T3N0M0	3	+	-	Lung
25	52	М	T3N0M0	3	+	+	RPLN
26	65	М	T4N0M0	3	+	+	Urinary bladder
27	71	М	T3N0M0	2	+	+	Urinary bladder
28	63	М	T2NxM0	3	+	+	-
29	65	М	T3N0M0	3	+	+	-
30	67	Μ	T3N1M0	3	+	+	RPLN
31	67	M	T3NxM0	2	+	+	RPLN
32	76	M	T1NxM0	2	-	-	-
33	82	M	T1NxM0	2			
34	69	M	T2NxM0	$\frac{2}{2}$	-	-	Urinary bladder
35	45	M	T1NxM0	2	-	-	Urinary bladder
35 36	43 64	M			-	-	Utiliary Diadder
30 37			T1NxM0	2 2	-	-	-
	74 77	M	T1NxM0		-	-	- T 1
38	77	М	T3N0M0	2	+	-	Local recurrence
39	72	F	T2NxM0	3	-	-	Urinary bladder
40	76	М	T2NxM0	2	+	-	-
41	70	M	T1NxM0	2	-	-	-
42	82	F	T1NxM0	2	-	-	-
43	74	М	T3N0M0	2	-	-	Urinary bladder
44	75	М	T1NxM0	2	-	-	Urinary bladder
45	82	Μ	T2NxM0	3	+	+	-
46	64	М	T1NxM0	2	-	-	-
47	67	М	T1NxM0	2	-	-	-
48	85	F	T4N0M0	3	+	+	RPLN
49	72	F	T3N0M0	3	+	+	Urinary bladder
50	55	М	T2NxM0	2	+	-	-
51	85	Μ	T1NxM0	2	-	-	-
					+	+	RPLN
52	67	M	T4N0M0	3	+	+	RPLN

LVI, lymphovascular invasion; 5-FU, 5-fluorouracil; RPLN, retroperitoneal lymph node.

Figure S1. Association between the expression levels of 5-FU metabolism-related enzymes and clinical outcomes, excluding patients who received adjuvant 5-FU chemotherapy. Among the patients who did not receive adjuvant 5-FU chemotherapy, the overall survival rates (shown by Kaplan-Meier curves) for those with higher expression levels of (A) DPD, (B) OPRT and (C) TS in their primary tumors were compared with those showing lower expression. The progression-free survival rates (shown by Kaplan-Meier curves) for the patients with higher expression levels of (D) DPD, (E) OPRT and (F) TS were also compared. The patients with higher expression levels of TS and the patients with lower expression levels of DPD exhibited lower progression-free survival rates (P<0.05 determined by log rank test). NS, not significant; 5-FU, 5-fluorouracil; DPD, dihydropyrimidine dehydrogenase; OPRT, orotatephosphoribosyltransferase; TS, thymidylate synthase.




Figure S2. Association between the efficacy of adjuvant 5-FU chemotherapy and the expression of *OPRT*. (A) The overall survival rates (shown by Kaplan-Meier curves) of patients with lower expression levels of *OPRT* who received adjuvant 5-FU chemotherapy were compared with those of patients who did not. The UC-UUT patients who received 5-FU all had LVI, and among those who did not receive 5-FU, some had LVI and some did not. No significant differences were observed. (B) The overall survival rates (shown by Kaplan-Meier curves) of patients with higher expression levels of *OPRT* who received adjuvant 5-FU chemotherapy were compared with those of patients who did not. The UC-UUT patients who received 5-FU all had LVI, and among those who did not receive 5-FU, some had LVI and some did not. No significant differences were observed. (C) The overall survival rates (shown by Kaplan-Meier curves) of patients with lower expression levels of *OPRT* who received adjuvant 5-FU chemotherapy were compared with those of patients with lower expression levels of *OPRT* who received adjuvant 5-FU chemotherapy were compared with those of patients with lower expression levels of *OPRT* who received adjuvant 5-FU chemotherapy were compared with those of patients with lower expression levels of *OPRT* who received adjuvant 5-FU chemotherapy were compared with those of patients with lower expression levels of *OPRT* who received adjuvant 5-FU chemotherapy were compared with those of patients with lower expression levels of *OPRT* who also received the therapy. The two groups were compared with the same 3 group comparisons, and no significant differences were observed. NS, not significant; LVI, lymphovascular invasion; 5-FU, 5-fluorouracil; UC-UUT, urothelial carcinoma of the upper urinary tract; OPRT, orotatephosphoribosyltransferase.




Figure S3. Association between the efficacy of adjuvant 5-FU chemotherapy and the expression of *TS*. (A) The overall survival rates (shown by Kaplan-Meier curves) of patients with lower expression levels of *TS* who received adjuvant 5-FU chemotherapy were compared with those of patients who did not. The UC-UUT patients who received 5-FU all had LVI, and among those who did not receive 5-FU, some had LVI and some did not. No significant differences were observed. (B) The overall survival rates (shown by Kaplan-Meier curves) of patients with higher expression levels of *TS* who received adjuvant 5-FU chemotherapy were compared with those of patients who did not. The UC-UUT patients who received adjuvant 5-FU chemotherapy were compared with those of patients who did not. The UC-UUT patients who received 5-FU all had LVI, and among those who did not receive 5-FU, some had LVI and some did not. No significant differences were observed. (C) The overall survival rates (shown by Kaplan-Meier curves) of patients with lower expression levels of *TS* who received adjuvant 5-FU chemotherapy were compared with those of patients with lower expression levels of *TS* who received adjuvant 5-FU chemotherapy were (shown by Kaplan-Meier curves) of patients with lower expression levels of *TS* who received adjuvant 5-FU chemotherapy were compared with those of patients with lower expression levels of *TS* who received adjuvant 5-FU chemotherapy were compared with those of patients with lower expression levels of *TS* who received adjuvant 5-FU chemotherapy were compared with those of patients with lower expression of *TS* who also received the therapy. The two groups were comprised of UC-UUT patients with LVI. No significant differences were observed. (D-F) Progression-free survival rates were also investigated with the same 3 group comparisons, and no significant differences were observed. NS, not significant; LVI, lymphovascular invasion; 5-FU, 5-fluorouracil; UC-UUT, urothelial carcinoma of the upper urinary tract; TS, thymid

